Aker BioMarine ASA: Disclosure of large shareholding and mandatory notification of trade

Reference is made to the merger between Aker BioMarine ASA (the "Company") and Aker Capital NewCo AS (“MergerCo”), an indirect wholly-owned subsidiary of Aker ASA (“Aker"), announced on 16 July 2026 and approved by an extraordinary general meeting of the Company on 17 August 2026 (the “Merger”).

As a preparatory step for completion of the Merger, Aker Capital AS (“Aker Capital”), a wholly-owned subsidiary of Aker and a legal person closely associated with Frank O. Reite, a member of the board of the Company, has today transferred all of its 69,065,940 shares in the Company, equal to approximately 78.73% of the shares and votes in the Company, to MergerCo, a wholly-owned subsidiary of Aker Capital. Finanstilsynet (the Financial Supervisory Authority of Norway) has pursuant to section 6-2 (3) of the Norwegian Securities Trading Act granted an exemption from the mandatory offer obligation for the transfer.

As previously announced, Aker Capital is also party to a forward contract with respect to 10,707,629 shares in the Company, comprising the shares for which acceptances were received under Aker Capital’s optional cash offer for all shares in the Company announced on 16 July 2026. The shares underlying the forward contract represent approximately 12.21% of the shares and votes in the Company.

This information is subject to the disclosure requirements pursuant to Article 19 of Regulation EU 596/2014 (the EU Market Abuse Regulation) and sections 4-2 and 5-12 of the Norwegian Securities Trading Act. Please refer to the attached PDMR form for further details.